• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

验证数据展示

  • FC experiment of human PBMCs using 65586-1-MR

    FC experiment of human PBMCs using 65586-1-MR

    1x10^6 unstimulated or PHA stimulated human PBMCs were surface stained with 0.25 ug Anti-Human PD-1 (CD279) Mouse IgG2a Recombinant Antibody (65586-1-MR, Clone: EH12.2H7) and CoraLite®488-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L). Cells were then stained with CoraLite® Plus 647 Anti-Human CD3. Cells were not fixed.

  • FC experiment of human PBMCs using 65586-1-MR

    FC experiment of human PBMCs using 65586-1-MR

    1x10^6 unstimulated (black) or PHA stimulated human PBMCs (red) were surface stained with 0.25 ug Anti-Human PD-1 (CD279) Mouse IgG2a Recombinant Antibody (65586-1-MR, Clone: EH12.2H7) and CoraLite®488-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L). 1x10^6 PHA treated human PBMCs were surface stained with Mouse IgG2a Isotype Control (65208-1-Ig, Clone: C1.18.4) and CoraLite®488-Conjugated AffiniPure Donkey Anti-Mouse IgG(H+L) (blue). Cells were not fixed.

Anti-Human PD-1/CD279 (EH12.2H7) Mouse IgG2a Recombinant Antibody

PD-1/CD279 Uni-rAbTM Recombinant Antibody for FC
Cat No. 65586-1-MR

Print datasheet

CloneNo. EH12.2H7

Host / Isotype

Mouse / IgG2a

Reactivity

human

Applications

FC

Synonyms

PD-1 (CD279), CD279, PD1, PD-1, PD 1

Formulation:  PBS and Azide
PBS and Azide
PBS Only
Conjugate:  Unconjugated
Size: 

-/ -

点击咨询售前客服

点击咨询售后客服

经过测试的应用

Positive FC detected inPHA treated human PBMCs
Planning an IHC experiment? We recommend our IHCeasy PD-1 Ready-To-Use IHC Kit. PD-1 primary antibody included.

推荐稀释比

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

65586-1-MR targets PD-1/CD279 in FC applications and shows reactivity with human samples.

Tested Applications FC Application Description
Tested Reactivity human
Immunogen N/A 种属同源性预测
Host / Isotype Mouse / IgG2a
Class Recombinant
Type Antibody
Full Name programmed cell death 1
Synonyms PD-1 (CD279), CD279, PD1, PD-1, PD 1
Calculated Molecular Weight 288 aa, 32 kDa
GenBank Accession NumberBC074740
Gene Symbol PD-1
Gene ID (NCBI) 5133
RRIDAB_3670336
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 0.09% sodium azide.
Storage ConditionsStore at 2-8°C. Stable for one year after shipment.

背景介绍

Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436).

实验方案

Product Specific Protocols
FC protocol for PD-1/CD279 antibody 65586-1-MRDownload protocol
Standard Protocols
Click here to view our Standard Protocols